- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy Advances for Epithelial Ovarian Cancer
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 12, Pages 3733
Publisher
MDPI AG
Online
2020-12-14
DOI
10.3390/cancers12123733
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic gene expression signature for high-grade serous ovarian cancer
- (2020) J. Millstein et al. ANNALS OF ONCOLOGY
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploiting the folate receptor α in oncology
- (2020) Mariana Scaranti et al. Nature Reviews Clinical Oncology
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity
- (2020) Eleni Gavriilaki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
- (2020) Anders Handrup Kverneland et al. Oncotarget
- Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
- (2020) Matthew S. Block et al. Nature Communications
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Synthetic lethality guiding selection of drug combinations in ovarian cancer
- (2019) Andreas Heinzel et al. PLoS One
- Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
- (2019) Jiang Lv et al. Journal of Hematology & Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in Ovarian Cancer
- (2019) Weimin Wang et al. Surgical Oncology Clinics of North America
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum Derivatives Effects on Anticancer Immune Response
- (2019) Cédric Rébé et al. Biomolecules
- Latest developments in MUC1 immunotherapy
- (2018) Joyce Taylor-Papadimitriou et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
- (2018) Maren Knödler et al. BRITISH JOURNAL OF CANCER
- Helicase-driven activation of NFκB-COX2 mediates the immunosuppressive component of dsRNA-driven inflammation in the human tumor microenvironment
- (2018) Marie-Nicole Theodoraki et al. CANCER RESEARCH
- T-cell responses toTP53"hotspot" mutations and unique neoantigens expressed by human ovarian cancers
- (2018) Drew C Deniger et al. CLINICAL CANCER RESEARCH
- Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
- (2018) Eric Pujade-Lauraine et al. Future Oncology
- Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy
- (2018) Chien-Fu Hung et al. HUMAN GENE THERAPY
- Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
- (2018) Janos L. Tanyi et al. Science Translational Medicine
- Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer
- (2018) Sara Bobisse et al. Nature Communications
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
- (2018) Abdi Ghaffari et al. BRITISH JOURNAL OF CANCER
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- In vivo cancer vaccination: Which dendritic cells to target and how?
- (2018) Cheryl Lai-Lai Chiang et al. CANCER TREATMENT REVIEWS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
- (2018) Shannon Grabosch et al. ONCOGENE
- Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
- (2018) Ying L. Liu et al. Current Oncology Reports
- Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
- (2018) Diana Cholakian Pearre et al. Therapeutics and Clinical Risk Management
- Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells
- (2018) John P. Murad et al. Frontiers in Immunology
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- High grade serous ovarian carcinomas originate in the fallopian tube
- (2017) S. Intidhar Labidi-Galy et al. Nature Communications
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer
- (2016) J. Krzystyniak et al. ANNALS OF ONCOLOGY
- Opportunities in immunotherapy of ovarian cancer
- (2016) G. Coukos et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies
- (2016) Kari L. Ring et al. CANCER JOURNAL
- Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
- (2016) Kenneth H. Kim et al. GYNECOLOGIC ONCOLOGY
- Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
- (2016) Dmitriy Zamarin et al. GYNECOLOGIC ONCOLOGY
- Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
- (2016) Avery D. Posey et al. IMMUNITY
- Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- (2016) Mark O'Hara et al. Immunotherapy
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
- (2016) Ignace Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
- (2016) Wei Xue et al. OncoImmunology
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells
- (2015) B L Levine CANCER GENE THERAPY
- Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model
- (2015) Jyothi Thyagabhavan Mony et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
- (2015) X. Liu et al. CANCER RESEARCH
- Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity
- (2015) Tsukasa Seya et al. CANCER SCIENCE
- The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy
- (2015) E. Zsiros et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
- (2015) L. Corrales et al. CLINICAL CANCER RESEARCH
- Cancer gene therapy with T cell receptors and chimeric antigen receptors
- (2015) Hans J Stauss et al. CURRENT OPINION IN PHARMACOLOGY
- Advances and prospects in adoptive cell transfer therapy for ovarian cancer
- (2015) Katarzyna Urbanska et al. Immunotherapy
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- IMGN853, a Folate Receptor- (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors
- (2015) O. Ab et al. MOLECULAR CANCER THERAPEUTICS
- Checkpoint blockade in combination with cancer vaccines
- (2015) Michael A. Morse et al. VACCINE
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy
- (2015) Emese Zsiros et al. OncoImmunology
- Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge
- (2015) Stefan Symeonides et al. Frontiers in Oncology
- NKG2D CARs as Cell Therapy for Cancer
- (2014) Charles L. Sentman et al. CANCER JOURNAL
- Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer
- (2014) E. Galanis et al. CANCER RESEARCH
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- MUC16: molecular analysis and its functional implications in benign and malignant conditions
- (2014) Dhanya Haridas et al. FASEB JOURNAL
- A Human ErbB2-Specific T-Cell Receptor Confers Potent Antitumor Effector Functions in Genetically Engineered Primary Cytotoxic Lymphocytes
- (2014) Evripidis Lanitis et al. HUMAN GENE THERAPY
- Mechanism of Action of Immunotherapy
- (2014) Mary L. Disis SEMINARS IN ONCOLOGY
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
- (2014) K. Odunsi et al. Cancer Immunology Research
- Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
- (2013) C. J. Nirschl et al. CLINICAL CANCER RESEARCH
- A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside
- (2013) C. L.-L. Chiang et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Monoclonal antibodies therapies for ovarian cancer
- (2013) Umberto Leone Roberti Maggiore et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
- (2013) Deborah K. Armstrong et al. GYNECOLOGIC ONCOLOGY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Major clinical research advances in gynecologic cancer in 2011
- (2012) Dong Hoon Suh et al. Journal of Gynecologic Oncology
- BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
- (2012) Jessica N McAlpine et al. MODERN PATHOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunobiology of human mucin 1 in a preclinical ovarian tumor model
- (2012) R A Budiu et al. ONCOGENE
- MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches
- (2012) D W Kufe ONCOGENE
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
- (2012) Shan Wan et al. PLoS One
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
- (2012) K. Odunsi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer
- (2011) Raluca A. Budiu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
- (2011) Yu-Li Chen et al. Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
- (2011) Gina Mantia-Smaldone et al. Cancer Management and Research
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- Oncolytic virotherapy of gynecologic malignancies
- (2010) Andreas D. Hartkopf et al. GYNECOLOGIC ONCOLOGY
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Whole tumor antigen vaccines
- (2010) Cheryl Lai-Lai Chiang et al. SEMINARS IN IMMUNOLOGY
- The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
- (2009) Xia Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
- (2009) Peter J. Frederick et al. GYNECOLOGIC ONCOLOGY
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
- (2009) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- Folate receptor alpha as a tumor target in epithelial ovarian cancer
- (2008) Kimberly R. Kalli et al. GYNECOLOGIC ONCOLOGY
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations
- (2008) Ann K. Folkins et al. GYNECOLOGIC ONCOLOGY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss
- (2008) Blaise Clarke et al. MODERN PATHOLOGY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells
- (2007) Hans J. Stauss et al. BLOOD CELLS MOLECULES AND DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search